ArQule To Report Second Quarter 2016 Financial Results On August 3, 2016
July 20, 2016 07:00 ET
|
ArQule, Inc.
BURLINGTON, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced it will report financial results for the second quarter 2016 before the market opens on Wednesday,...
ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference
July 18, 2016 16:00 ET
|
ArQule, Inc.
Data supports further preclinical and clinical research in BTK sensitive and ibrutinib resistant malignancies BURLINGTON, Mass., July 18, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today...
ArQule to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 12, 2016
July 05, 2016 07:00 ET
|
ArQule, Inc.
BURLINGTON, Mass., July 05, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of...
ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
June 30, 2016 07:00 ET
|
ArQule, Inc.
75% disease control rate, including a 25% objective response rate, was observed in 12 evaluable patients harboring FGFR2 genetic alterations BURLINGTON, Mass., June 30, 2016 (GLOBE NEWSWIRE) --...
ArQule to Present Preliminary Phase 1/2 Data for FGFR Inhibitor, ARQ 087, in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
June 23, 2016 07:00 ET
|
ArQule, Inc.
BURLINGTON, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that preliminary data from the ongoing phase 2 portion of a phase 1/2 trial in intrahepatic...
ArQule Reports First Quarter 2016 Financial Results
May 04, 2016 07:00 ET
|
ArQule, Inc.
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced its financial results for the first quarter of...
ArQule To Report First Quarter 2016 Financial Results On May 4, 2016
April 20, 2016 07:30 ET
|
ArQule, Inc.
BURLINGTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced it will report financial results for the first quarter 2016 before the market opens on Wednesday, May...
ArQule to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016
April 05, 2016 07:30 ET
|
ArQule, Inc.
BURLINGTON, Mass., April 05, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of...
Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular Carcinoma
Independent Data Monitoring Committee (DMC) Conducts Interim Assessment BURLINGTON, Mass. and PARSIPPANY, N.J., March 22, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) and Daiichi Sankyo...
ArQule Reports Fourth Quarter and Full Year 2015 Financial Results
February 29, 2016 07:00 ET
|
ArQule, Inc.
Conference Call Scheduled Today at 9:00 a.m. ET BURLINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced its financial results for the fourth quarter and...